JAMA Intern Med:提醒装置能否改善依从性较差个体的药物依从性?

2017-05-22 何娜 吴星 环球医学

3种低成本提醒装置是否可以改善接受治疗但依从性较差个体的药物依从性?2017年5月,发表在《JAMA Intern Med》的一项针对美国药品福利管理者53480例参与者的随机临床试验中,没有发现对照组与使用提醒装置组之间的药物依从性存在显着差异(可切换的药品条、数字定时盖,或标准药盒)。

3种低成本提醒装置是否可以改善接受治疗但依从性较差个体的药物依从性?2017年5月,发表在《JAMA Intern Med》的一项针对美国药品福利管理者53480例参与者的随机临床试验中,没有发现对照组与使用提醒装置组之间的药物依从性存在显着差异(可切换的药品条、数字定时盖,或标准药盒)。



重要性:健忘是慢性疾病药物依从性差的一个重大因素,这个问题可以通过药物提醒装置进行解决。

目的:比较3种低成本提醒装置对药物依从性的影响。

设计、地点和受试者:该4组随机区组临床试验纳入美国CVS Caremark药品福利管理者中53480例参与者。符合纳入标准的受试者年龄在18至64岁,且长期使用1种至3种口服药物;在随机前12个月,受试者对所有处方治疗的依从性欠佳(药物占有率为30%至80%)。随机时基于受试者正在使用的药物对受试者进行分层:心血管或其他非抑郁慢性疾病药物(慢性疾病层)和抗抑郁药物(抗抑郁层)。对每一层,在由患者所用药物是否定量每日1次定义的区域内进行随机。患者被随机至邮件接受可切换的药品条、数字定时盖,或标准药盒。对照组既不接受通知也不使用装置。收集2013年2月12日至2015年3月21日期间的数据,基于意向治疗人群对数据进行分析。

主要结局和测量指标:主要结局为12个月的随访期间内慢性疾病层患者对所有符合纳入标准的药物的依从性得到优化(药物占有率≥80%),利用药品赔付数据进行确定。次要结局包括慢性疾病层患者心血管药物依从性的优化,以及抗抑郁药依从性的优化。

结果:在53480例受试者中,平均(SD)年龄为45(12)岁,56%为女性。在初步分析中, 15.5%被分配至标准药盒组的慢性疾病层的患者、15.1%被分配至数字定时盖组的患者、16.3被分配至可切换的药品条组的患者和15.1%被分配至对照组的患者在随访期间对其处方治疗的依从性得到优化。对照组与任何装置组之间在依从性优化比值方面没有显着差异(标准药盒组:比值比[OR],1.03 [95% CI,0.95~1.13];数字定时盖组:OR,1.00 [95% CI,0.92~1.09];可切换的药品条组:OR,0.94 [95% CI,0.85~1.04])。在直接比较中,标准药盒组的依从性高于可切换的药品条组(OR,1.10 [95% CI, 1.00~1.21])。次要分析产生的结果相似。

结论和相关性:低成本提醒装置不能改善使用3种药物治疗常见慢性病的患者的依从性。若针对依从性更差的个体或实施确保药物持续使用的干预策略,则这些装置或许会更有效果。

意义:今后的研究应该主要集中于确保药物持续使用的策略的干预效果。

原始出处:

Choudhry NK1, Krume AA, et al. Effect of Reminder Devices on Medication Adherence: The REMIND Randomized Clinical Trial. JAMA Intern Med. 2017 May 1;177(5):624-631. doi: 10.1001/jamainternmed.2016.9627.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2032289, encodeId=e8542032289dd, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Thu Dec 28 19:25:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319272, encodeId=7bba13192e2b0, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed May 24 08:25:00 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607546, encodeId=b21d160e546ac, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed May 24 08:25:00 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201460, encodeId=9d262014602f, content=呵呵, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Tue May 23 05:52:08 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201346, encodeId=bd6c201346b3, content=结果出乎意料呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/MnthNYiaYT4SNKeEmLuaew8INxnWjegguR2tEB5XL37oicS1HFZDejzeXjjFpdPVZ2VaLzXibdTXkkPRuj4YVQkTg/132, createdBy=76cb105999, createdName=穆慕仁真, createdTime=Mon May 22 22:05:39 CST 2017, time=2017-05-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2032289, encodeId=e8542032289dd, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Thu Dec 28 19:25:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319272, encodeId=7bba13192e2b0, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed May 24 08:25:00 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607546, encodeId=b21d160e546ac, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed May 24 08:25:00 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201460, encodeId=9d262014602f, content=呵呵, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Tue May 23 05:52:08 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201346, encodeId=bd6c201346b3, content=结果出乎意料呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/MnthNYiaYT4SNKeEmLuaew8INxnWjegguR2tEB5XL37oicS1HFZDejzeXjjFpdPVZ2VaLzXibdTXkkPRuj4YVQkTg/132, createdBy=76cb105999, createdName=穆慕仁真, createdTime=Mon May 22 22:05:39 CST 2017, time=2017-05-22, status=1, ipAttribution=)]
    2017-05-24 fyxzlh
  3. [GetPortalCommentsPageByObjectIdResponse(id=2032289, encodeId=e8542032289dd, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Thu Dec 28 19:25:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319272, encodeId=7bba13192e2b0, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed May 24 08:25:00 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607546, encodeId=b21d160e546ac, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed May 24 08:25:00 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201460, encodeId=9d262014602f, content=呵呵, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Tue May 23 05:52:08 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201346, encodeId=bd6c201346b3, content=结果出乎意料呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/MnthNYiaYT4SNKeEmLuaew8INxnWjegguR2tEB5XL37oicS1HFZDejzeXjjFpdPVZ2VaLzXibdTXkkPRuj4YVQkTg/132, createdBy=76cb105999, createdName=穆慕仁真, createdTime=Mon May 22 22:05:39 CST 2017, time=2017-05-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2032289, encodeId=e8542032289dd, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Thu Dec 28 19:25:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319272, encodeId=7bba13192e2b0, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed May 24 08:25:00 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607546, encodeId=b21d160e546ac, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed May 24 08:25:00 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201460, encodeId=9d262014602f, content=呵呵, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Tue May 23 05:52:08 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201346, encodeId=bd6c201346b3, content=结果出乎意料呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/MnthNYiaYT4SNKeEmLuaew8INxnWjegguR2tEB5XL37oicS1HFZDejzeXjjFpdPVZ2VaLzXibdTXkkPRuj4YVQkTg/132, createdBy=76cb105999, createdName=穆慕仁真, createdTime=Mon May 22 22:05:39 CST 2017, time=2017-05-22, status=1, ipAttribution=)]
    2017-05-23 lou.minghong

    呵呵

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2032289, encodeId=e8542032289dd, content=<a href='/topic/show?id=69a28e674a6' target=_blank style='color:#2F92EE;'>#药物依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87674, encryptionId=69a28e674a6, topicName=药物依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Thu Dec 28 19:25:00 CST 2017, time=2017-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319272, encodeId=7bba13192e2b0, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Wed May 24 08:25:00 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1607546, encodeId=b21d160e546ac, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed May 24 08:25:00 CST 2017, time=2017-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201460, encodeId=9d262014602f, content=呵呵, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib2JlGvwpAibiaovVhfA9DbO7X7JLGGjM4Cic6oMgxLdnuS9piaP9cnG2OwIbkzHvX0qzS1boibyYNqR5vHZu7HQs5EIB/0, createdBy=298d1398341, createdName=lou.minghong, createdTime=Tue May 23 05:52:08 CST 2017, time=2017-05-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=201346, encodeId=bd6c201346b3, content=结果出乎意料呀, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/MnthNYiaYT4SNKeEmLuaew8INxnWjegguR2tEB5XL37oicS1HFZDejzeXjjFpdPVZ2VaLzXibdTXkkPRuj4YVQkTg/132, createdBy=76cb105999, createdName=穆慕仁真, createdTime=Mon May 22 22:05:39 CST 2017, time=2017-05-22, status=1, ipAttribution=)]
    2017-05-22 穆慕仁真

    结果出乎意料呀

    0

相关资讯

Drugs Aging:如何改善老年人的药物依从性和健康结局?

老年患者普遍存在用药依从性差的问题。2017年3月,发表在《Drugs Aging》的一项随机对照试验的循证评价,考察了改善药物依从性的干预是否也可改善居住在社区的老年人的健康结局。背景:老年患者中,较差药物依从性是一项主要的公共卫生问题,常造成不良健康结局。目的:本综述的目的是提供随机对照研究的更新的证据摘要,从而确定旨在改善药物依从性的干预是否也可改善居住在社区的老年人的健康结局。方法:评估老